Study #2025-1634
ASCEND-CRC: Profiling and targeting dynamic tumor resistance in patients with metastatic colorectal cancer
MD Anderson Study Status
Enrolling
Treatment Agent
Bevacizumab, Cetuximab, Panitumumab, FOLFIRI, FOLFOX, Encorafenib, Adagrasib, Trifluridine/tipiracil (TAS-102), Trastuzumab deruxtecan, Tucatinib, Sotorasib
Description
To find out if certain drug/therapy combinations that are targeted to individual patients based on characteristics of their disease types may help to control the disease.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Dynamic Tumor Resistance, Metastatic Colorectal Cancer
Study phase:
Phase I (Early)
Physician name:
Edmund Kopetz
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.